非阵发性心房颤动肺静脉隔离联合与不联合左心耳结扎:aMAZE随机临床试验
这项多中心、前瞻性、开放标签随机临床试验纳入非阵发性心房颤动患者,按2:1随机分配至左心耳结扎联合肺静脉隔离组(404例)或单纯肺静脉隔离组(206例)。主要有效性终点方面,联合组12个月无心律失常率为64.3%,单纯组为59.9%,差异为4.3%(贝叶斯95%可信区间 -4.2% 至 13.2%),未达到预设的优效性统计标准;30天严重不良事件率为3.4%,低于预设的10%安全性阈值。
要点
- 左心耳结扎联合肺静脉隔离未达到预设优效性标准(后验优效概率0.835,预设阈值0.977)。
- 30天严重不良事件率3.4%,低于预设10%的性能目标,安全性终点达标。
- 12个月完全左心耳封闭(0 mm残余交通)率为84%,≤5 mm残余交通率为99%。
核心结论
- 在非阵发性心房颤动患者中,经皮左心耳结扎联合肺静脉隔离在12个月无心律失常方面未达到预设的有效性标准,但达到了预设的安全性标准,并显示12个月时左心耳封闭率较高。
研究设计与样本
- 多中心、前瞻性、开放标签、随机临床试验,于2015年10月至2019年12月在美国53个中心入组,末次随访日期为2021年4月21日。
- 纳入非阵发性心房颤动持续时间小于3年的患者,按2:1比例随机分配至左心耳结扎联合肺静脉隔离组(404例)或单纯肺静脉隔离组(206例)。
主要发现
- 主要有效性终点(肺静脉隔离术后12个月无记录到的持续时间大于30秒的心房心律失常)为左心耳结扎联合肺静脉隔离组64.3% vs 单纯肺静脉隔离组59.9%,差异4.3%(贝叶斯95%可信区间 -4.2% 至 13.2%),后验优效概率0.835,未达到预设的优效性统计标准0.977。
- 主要安全性终点(预设严重不良事件复合终点)30天发生率为3.4%(贝叶斯95%可信区间 2.0% 至 5.0%;后验概率1.0),低于预设的10%性能目标。
- 肺静脉隔离术后12个月,完全左心耳封闭(0 mm残余交通)见于84%的患者,残余交通≤5 mm见于99%的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Left atrial appendage elimination may improve catheter ablation outcomes for atrial fibrillation. OBJECTIVE: To assess the safety and effectiveness of percutaneous left atrial appendage ligation adjunctive to catheter pulmonary vein isolation for nonparoxysmal atrial fibrillation. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective, open-label, randomized clinical trial evaluated the safety and effectiveness of percutaneous left atrial appendage ligation adjunctive to planned pulmonary vein isolation for nonparoxysmal atrial fibrillation present for less than 3 years. Eligible patients were randomized in a 2:1 ratio to undergo left atrial appendage ligation and pulmonary vein isolation or pulmonary vein isolation alone. Use of a 2:1 randomization ratio was intended to provide more device experience and safety data. Patients were enrolled from October 2015 to December 2019 at 53 US sites, with the final follow-up visit on April 21, 2021. INTERVENTIONS: Left atrial appendage ligation plus pulmonary vein isolation compared with pulmonary vein isolation alone. MAIN OUTCOMES AND MEASURES: A bayesian adaptive analysis was used for primary end points. Primary effectiveness was freedom from documented atrial arrythmias of greater than 30 seconds duration 12 months after undergoing pulmonary vein isolation. Rhythm was assessed by Holter monitoring at 6 and 12 months after pulmonary vein isolation, symptomatic event monitoring, or any electrocardiographic tracing obtained through 12 months after pulmonary vein isolation. Primary safety was a composite of predefined serious adverse events compared with a prespecified 10% performance goal 30 days after the procedure. Left atrial appendage closure was evaluated through 12 months after pulmonary vein isolation. RESULTS: Overall, 404 patients were randomized to undergo left atrial appendage ligation plus pulmonary vein isolation and 206 were randomized to undergo pulmonary vein isolation alone. Primary effectiveness was 64.3% with left atrial appendage ligation and pulmonary vein isolation and 59.9% with pulmonary vein isolation only (difference, 4.3% [bayesian 95% credible interval, -4.2% to 13.2%]; posterior superiority probability, 0.835), which did not meet the statistical criterion to establish superiority (0.977). Primary safety was met, with a 30-day serious adverse event rate of 3.4% (bayesian 95% credible interval, 2.0% to 5.0%; posterior probability, 1.0) which was less than the prespecified threshold of 10%. At 12 months after pulmonary vein isolation, complete left atrial appendage closure (0 mm residual communication) was observed in 84% of patients and less than or equal to 5 mm residual communication was observed in 99% of patients. CONCLUSIONS AND RELEVANCE: Percutaneous left atrial appendage ligation adjunctive to pulmonary vein isolation did not meet prespecified efficacy criteria for freedom from atrial arrhythmias at 12 months compared with pulmonary vein isolation alone for patients with nonparoxysmal atrial fibrillation, but met prespecified safety criteria and demonstrated high rates of closure at 12 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02513797.
引用
- Lakkireddy DR, Wilber DJ, Mittal S, et al. Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial. JAMA. 2024. PMID: 38563835. doi:10.1001/jama.2024.3026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。